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Abstract
Pharmacological inhibition of dietary lipid absorption induces favorable changes in serum lipoprotein levels
in patients that are at risk for cardiovascular disease and is considered an adjuvant or alternative treatment
with HMG-CoA reductase inhibitors (statins). Here we demonstrate the feasibility of identifying novel
inhibitors of intestinal lipid absorption using the zebrafish system. A pilot screen of an unbiased chemical
library identified novel compounds that inhibited processing of fluorescent lipid analogues in live zebrafish
larvae. Secondary assays identified those compounds suitable for testing in mammals and provided insight
into mechanism of action, which for several compounds could be distinguished from ezetimibe, a drug used
to inhibit cholesterol absorption in humans that broadly inhibited lipid absorption in zebrafish larvae. These
findings support the utility of zebrafish screening assays to identify novel compounds that target complex
physiological processes.
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larvae. These findings support the utility of zebrafish screening assays to identify novel compounds that target complex
physiological processes.
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Introduction
Inhibition of dietary lipid absorption is an evolving strategy to
treat cardiovascular complications of disorders of lipid metabo-
lism. Two commonly used drugs in this class of pharmacological
agents, orlistat and ezetimibe improve the serum lipoprotein
profiles of patients that are at high risk for acute coronary
syndrome, stroke and sudden death, and therefore may be used as
an adjuvant or alternative to HMG co-reductase inhibitors (statins)
for the primary and secondary prevention of these disorders [1–5].
Although confirmation of the efficacy of this pharmacological
approach awaits completion of large clinical trials, the adjuvant
use of these compounds is common in patients that do not meet
targeted reductions of lipoproteins while taking statins [6–10].
Given the high prevalence of lipid metabolism disorders it is
desirable to identify lead compounds that can be developed into
new drugs that inhibit lipid absorption via novel mechanisms.
Here we report the utility of using the zebrafish for this purpose.
Because of their small size, optical transparency zebrafish larvae
are well suited for chemical library screens using fluorescent,
histochemical or morphological assays [11–16]. Indeed, a great
advantage of chemical screens in zebrafish is the ability to rapidly
assess compound efficacy and toxicity in vivo. Given the high
degree of conservation of lipid metabolism in teleost fish and
mammals [17–20], it is likely that compounds identified in a
zebrafish screen will act through comparable mechanisms in
mammals.
Here we report the results of a pilot screen of a non-biased
chemical library through which we identified 7 novel compounds
that inhibited the absorption of fluorescent lipid analogues. We
show that compounds identified in the primary screening assay
can be rapidly prioritized for testing in mammals using a variety of
simple, yet highly informative in vivo secondary assays. The
secondary assays also provided insights into the compounds’
mechanism of action, which could be distinguished from the effects
of orlistat and ezetimibe in zebrafish larvae. Surprisingly, we found
that ezetimibe inhibited absorption of not only cholesterol analog,
but also long chain fatty acid and phopholipid analogs. Together,
these findings demonstrate the feasibility of conducting screens for
compounds that interfere with complex physiological processes
using the zebrafish.
Results
The screening assays used for this study were derived from
previous work using fluorescent lipid reporters in zebrafish larvae
[19]. Following their ingestion, the fluorescent metabolites of these
reporters are first detected in the gallbladder of live larvae and
later the intestinal lumen following gallbladder contraction. The
compounds are used at low concentrations and they are rapidly
absorbed from the intestinal lumen, thus their fluorescence
emission is not detected in the intestinal lumen immediately after
ingestion or when absorption in inhibited. Fluorescence emission
from one of the analogues, the phospholipid PED-6, is quenched
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prior to metabolism by luminal phospholipase. Thin layer
chromatographic analyses of bile from adult fish, or total body
lipids of 5 dpf larvae, showed that PED-6, which is labeled with a
BODIPY labeled short chain fatty acid (C5) at the sn-2 position, is
metabolized to cholesterol esters, phospholipids and possibly,
triglyceride (19 and data not shown). Free PED6 was not detected
in either assay.
For the primary screen, 5 day post-fertilization larvae were
arrayed in 96 well plates and soaked overnight in test compounds
(25 uM in 2% DMSO). The following morning larvae were
soaked in PED-6 for 6 hours (Figure 1A, B) after which a
qualitative visual assessment of gallbladder fluorescence was made
using an inverted compound microscope. Reduced gallbladder
fluorescence, the endpoint we use to identify active compounds in
the primary screen, could not differentiate compounds that
inhibited lipid absorption from those that interfered with
swallowing, phospholipase activity or hepatic metabolism and
biliary secretion. As described below, secondary assays were
devised to distinguish these mechanistic possibilities.
Preliminary results of a pilot screen of 3,840 compounds from
the MLSCN library (http://mli.nih.gov/mli/) have been reported
(http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=686&loc=
ea_ras; http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=
691&loc=ea_ras). Here were identify three additional compounds
recovered in this screen and provide a detailed account of the
screening assay and the results of newly devised secondary assays
designed to define mechanism of action and prioritize compounds
for testing in mammalian models.
Larvae tolerated overnight incubation in the majority of the
3,840 compounds analyzed in the primary screen, however 67
compounds (1.75%) caused larval death or severely compromised
cardiac circulation and were therefore deemed toxic. 50
compounds (1.3%) caused either complete or partial inhibition
gallbladder fluorescence. When re-tested in a qualitative visual
assay of PED-6 metabolism, 15 of these compounds were
considered active in a dose responsive fashion (0.3% of the total
number screened). 12 of the 15 compounds identified in the
primary screen were tested in adult fish; 5 compounds were
deemed active based on reduced gallbladder fluorescence derived
from PED-6 (not shown) while 7 were either inactive and or toxic
in adult fish and not studied further. Together with the 3
compounds that were not available in sufficient quantity to be
tested in adult fish, this left 8 compounds for testing in secondary
assays (Table S1).
The visual dose response assays conducted in larvae (n = 5)
arrayed in the 96 well plates showed that 2 of the 8 compounds
first inhibited PED-6 processing at 6.25 uM (compounds 2 and
10), whereas the remaining compounds were first active at 25 uM
(Figure 1C–H shows dose response for compound 2). In separate
experiments (described in the Methods section), combined
gallbladder and intestinal fluorescence of individual compound
treated larvae was quantified using fluorescence microscopy. This
showed that the active compounds reduced PED-6 metabolism
between 51%–67% (Figure 1I and Figure S1). Of the 8 active
compounds, only 1 has been used in humans; clofazimine
(compound 10), a rhiminophenazine dye with antimicrobial and
anti-inflammatory activity used to treat leprosy and other types of
mycobacterial infections [21]. Although intestinal toxicity has been
reported with long term use of high doses of this drug, no prior
reports of altered lipid absorption have been reported [22].
We devised a series of secondary assays that allowed us to
further characterize the active compounds’ mechanism of action
and prioritize them for testing in mammals.
We assayed the effect of the active compounds on the ingestion
of fluorescent microspheres to control for the possibility that they
prevented swallowing of PED-6 from the larvae’s aqueous media.
This assay confirmed normal swallowing in 7 of 8 active
compounds. Interestingly, the 1 compound that inhibited
swallowing (compound 1; Figure S2) had no obvious effect on
larval motility or cardiac function.
We assayed the effect of the active compounds on the
metabolism of fluorescent cholesterol and fatty acid analogues
because these dietary lipids are differentially absorbed and or
processed by enterocytes compared with the phospholipid used for
the primary screen, PED6.
Recent studies have shown that the intestinal absorption of
dietary cholesterol is dependent on the Neiman Pick Type C 1-
Like 1 protein [NPC1L1; 23, 24]. Although the function of
NPC1L1 is still debated, it is generally agreed upon that it as a
cholesterol transporter embedded within the apical enterocyte
membrane [25–27]. NPC1L1 has not been implicated in
phospholipid absorption, thus it was not predicted that the screen
compounds, which were identified by their inhibition of
phospholipid (PED-6) absorption, would interfere with absorption
Figure 1. Chemical screen identifies novel inhibitors of zebrafish lipid metabolism. (A, B) Bright field and fluorescent images of a 6 day
post-fertilization wild type zebrafish larva that had ingested the PED6 lipid reporter. Fluorescence is detected in the intestine (asterisk) and
gallbladder (arrow). (C–H) Representative dose response assay shows inhibition of PED6 metabolism in larvae treated with compound 2. Inhibition of
PED6 metabolism is first detected at 6.25 uM. Larvae (6 day post-fertilization) are arrayed in a 96-well plate. (I) Quantification of the effect of active
compounds (25 uM) on PED6 metabolism, as determined by total gallbladder and intestinal fluorescence measured in individual larvae. Error bars –
standard deviation.
doi:10.1371/journal.pone.0012386.g001
Zebrafish Lipid Absorption
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of a fluorescent cholesterol analog, NBD-cholesterol. Surprisingly,
each of the 7 active compounds inhibited metabolism of NBD-
cholesterol, as determined by levels of biliary and intestinal
fluorescence (Figure 2A, E, I and Figure S1).
We next measured the effect of the active compounds on the
absorption of fluorescent short chain fatty acid (SCFA) and long
chain fatty acid (LCFA) analogs. (Figure 2 and Figure S1). The
distinction between acyl-chain length is important because LCFA
are thought to be taken up from the intestinal lumen by a protein
mediated process whereas as SCFA are thought to enter the
enterocytes via simple diffusion [28,29]. In addition, LCFA
require incorporation into lipoprotein particles for transport from
enterocytes to the liver whereas SCFA enter the blood directly and
are transported bound to albumin and other serum proteins [29].
All 7 compounds inhibited metabolism of the LCFA C-16 bodipy
(Figure 2B, F, J) but only 2 had an effect on SCFA C-5 bodipy
metabolism (Figure 2C, G, D, H, K). Inhibition of native C5-
bodipy processing by compounds 2 and 11 (Figure 2K) was less
pronounced than inhibition of processing of LCFA, NBD-
cholesterol or PED6 (Figure 2J, I; 1I).
Each of the active compounds from the primary screen
inhibited PED6, NBD-cholesterol and Bodipy-C16 (LCFA)
metabolism. In contrast, orlistat, a pancreatic lipase inhibitor,
and ezetimibe, which targets NPC1L1, are reported to inhibit
absorption of only dietary 1 lipid class; triglycerides, and
cholesterol and structurally related phytosterols, respectively. To
determine whether the non-selectivity of the active compounds
arose from a non-specific disruption of endocytic absorptive
pathways in enterocytes, we assayed in vivo processing of the styryl
dye AM1-43. AM1-43 is a fixable derivative of FM1-43, a reagent
that has been extensively used to study endocytosis [30]. When
ingested by zebrafish larvae, AM1-43 strongly labels the apical
plasma membrane of enterocytes. The number and size of AM1-
43 labeled vesicles that can be detected in the cytoplasm of these
cells provides a qualitative assessment of bulk endocytosis through
the apical plasma membrane [31]. 3 of the 7 active compounds
(compounds 2, 7, A10) caused a marked reduction in AM1-43
processing (Figure 3A–D). Fluorescent cytoplasmic vesicles could
only be detected in small percentage of the enterocytes from these
larvae (n = a minimum of 10 sections from 7 compound treated
and wild type larvae). The vesicles that were detected were also
smaller and had lower fluorescent emission. The effect of the
remaining 4 compounds (10, 11, B10, B11; Figure 3E–H and data
not shown) was deemed less pronounced because a larger number
of fluorescent vesicles were detected in enterocytes of treated
larvae.
To determine whether the active compounds identified in the
primary screen affected other aspects of digestive physiology we
assayed protease activity using a quenched bodipy labeled casein
protein. Cleavage of this reporter by pancreatic proteases
generates fluorescent peptides that can be detected in the intestinal
lumen of wild type larvae [32]. Intestinal fluorescence derived
from the casein reporter was minimally reduced in larvae treated
with 5 of 7 compounds (compounds 2, 10, 11, B10, B11; Figure 4).
Treatment with 2 compounds (7 and compound A10) caused a
profound reduction in the metabolism of the casein reporter
(Figure 4).
Changes in gallbladder and intestinal fluorescence detected in
the primary screening assay detected could have arisen from a
reduction in either intestinal and or hepatic lipid processing. We
fed compound treated larvae egg yolk and after allowing time for
its absorption, we performed whole mount stainings using the
lipophilic dye oil red o (ORO) to determine whether yolk-derived
lipids accumulated in either organ (Figure 5). Wild type larvae fed
egg yolk had strong ORO staining of the anterior intestine, as well
as the blood stream, the latter arising from lipid in circulating
lipoproteins [17] (Figure 5A, B). Manual dissection of the intestine
showed that the ORO staining derived from small lipid droplets
Figure 2. Cholesterol and fatty acid metabolism in zebrafish larvae treated with novel lipid absorption inhibitors. (A–H)
Representative fluorescent images of live 6 day post-fertilization wild type and compound treated larvae following ingestion of NBD cholesterol (A, E),
the LCFA BdpC16 (B, F), and the SCFA BdpC5 (C, D, G, H). All compounds used at 25 uM. Larvae treated with compound 2 showed reduced
metabolism of NBD-cholesterol, BdpC16 (not shown), and BdpC5 whereas larvae treated with compound 7 have reduced metabolism of BdpC16, but
not BdpC5. (I, J, K) Effect of the active compounds on lipid reporter metabolism, as determined by gallbladder and intestinal fluorescence measured
from individual larvae. Red arrow - gallbladder; red asterisk - intestine. Error bars – standard deviation.
doi:10.1371/journal.pone.0012386.g002
Zebrafish Lipid Absorption
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within the enterocyte cytoplasm (data not shown). Lipid within the
intestinal lumen was not detected in any wild type larvae (n = 10).
Each of the 7 active compounds tested reduced intestinal lipid
(Figure 5C–H and data not shown). Lipid was detected in
enterocytes of all compound treated larvae, but at far lower levels
than in wild type, except in larvae treated with compound 10
(Figure 5E). Here luminal lipid was detected. No evidence of
hepatic lipid accumulation was evident. Collectively, these findings
are compatible with reduced intestinal lipid absorption in
compound treated larvae.
Compound synergy was examined in binary combinations of
the 7 remaining active compounds with each other and with
ezetimibe. Each compound was assayed at the highest concentra-
tion deemed inactive and the lowest dose considered active in the
visual dose response experiment. These experiments identified
potential synergism between compounds 2 and 10 (data not
shown).
The two most commonly prescribed lipid absorption inhibitors,
orlistat and ezetimibe, are generally considered to be selective
inhibitors of triglyceride, and cholesterol and phytosterol absorp-
tion, respectively. To gain a better understanding of the
mechanism of action of the novel compounds identified in our
screen, we examined how these drugs affected absorption of
fluorescent lipid reporters in zebrafish larvae.
Both drugs were assayed in an identical fashion as the screen
compounds. Orlistat had no effect on the metabolism of any of the
Figure 3. Endocytosis in zebrafish larvae treated with novel lipid absorption inhibitors. (A–H) Histological cross-sections through the
anterior intestine of control and compound treated larvae following ingestion of AM1-43. AM1-43 uptake is inhibited in larvae treated with
compounds 2, 7 and A10 whereas it is only slightly diminished in larvae treated with compounds 10, B10 and B11. Cell nuclei (blue) stained with Dapi.
All compounds used at 25 uM.
doi:10.1371/journal.pone.0012386.g003
Figure 4. Digestive protease activity in compound treated larvae. (A–C) Representative fluorescent images of live wild type and compound
treated larvae following ingestion of a quenched bodipy conjugate of casein. Bright fluorescence is seen in the intestine of the wild type larva and the
larva treated with compound 2, while minimal fluorescence is detected in the intestine of the larva treated with compound 7. (D) Quantification of
the effect of the active compounds on bodipy-casein metabolism, as determined by gall bladder and intestinal fluorescence measured from
individual larvae. Arrow - gallbladder; asterisk - intestine. Error bars – standard deviation. All compounds used at 25 uM.
doi:10.1371/journal.pone.0012386.g004
Zebrafish Lipid Absorption
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lipid reporters (data not shown). This was predicted, however
because none are processed by pancreatic lipase, which is
responsible for hydrolysis of triglycerides [33]. In contrast to
orlistat, ezetimibe was predicted to inhibit absorption of NBD-
cholesterol because the amino acid domain of dog Npc1l1
required for high affinity binding to ezetimibe [34,35] is highly
conserved in both human NPC1L1 and the predicted zebrafish
Npc1l1 protein (42 identical, 11 conserved and 10 non-conserved
residues; Figure S3). Indeed, larvae treated overnight with the
highest ezetimibe dose tested (50 uM) showed a 78% reduction of
gallbladder and intestinal fluorescence derived from NBD-
cholesterol (Figure 6A–C, J). Treatment with lower doses
(37.5 uM, 25 uM, 12.5 uM, 6.25 uM) showed proportionately
less inhibition (Figure S4). Unexpectedly, ezetimibe also reduced
metabolism of the phospholipid PED-6 and the saturated long
chain fatty acid (LCFA) Bodipy-C16 (Figure 6D, E, G, H, J). As
predicted, ezetimibe had minimal effect on the metabolism of
SCFA Bodipy-C5 (Figure 6F, I, J). ORO stainings of yolk-fed
larvae confirmed reduced lipid absorption was reduced by
ezetimibe treatment (Figure 5I). Ezetimibe had no effect on
digestive protease function in zebrafish larvae (data not shown).
Previous work suggests that ezetimibe interferes with intestinal
cholesterol absorption by disrupting the incorporation of
NPC1L1 into clathrin-coated vesicles [27]. This mechanism does
not predict that ezetimibe will interfere with fatty acid or
phospholipids uptake by enterocytes, neither of which are known
to be dependent on NPC1L1. Because of this, we speculated that
ezetimibe had a broader disruptive effect on intestinal endocytic
mechanisms. To examine this, we measured uptake of AM1-43
in ezetimibe treated larvae. Compared with control larvae,
ezetimibe (50 uM) treated larvae had a markedly reduced
number of AM1-43 labeled vesicles in enterocytes of the anterior
Figure 5. Reduced intestinal lipid absorption in ezetimibe and compound treated zebrafish larvae. (A–L) Lateral views of 6 day post-
fertilization larvae following fixation and staining with oil red o to mark neutral lipid. (A) Unfed wild type larva. (B) Wild type larva fed 1% egg yolk.
Arrows point to lipid in vasculature. (C–I) Compound treated larvae (25 uM) fed 1% egg yolk. There is reduced intestinal lipid in the compound
treated larvae, with no evidence of lipid in the vasculature. Hepatic lipid accumulation is not detected. Lipid is present in the intestinal lumen of
larvae treated with compound 10 and ezetimibe (50 uM; blue asterisk).
doi:10.1371/journal.pone.0012386.g005
Figure 6. Ezetimibe inhibits lipid metabolism in zebrafish larvae. (A) Bright field image of a 6 day post-fertilization wild type (wt) zebrafish
larva, lateral view. Red asterisk - intestine. (B–I) Gallbladder (red arrow) and intestinal (red asterisk) fluorescence in live 6 day post-fertilization wt and
ezetimibe (50 uM) treated larvae following ingestion of fluorescent lipid reporters. (B, C) NBD-cholesterol; (D, G) PED6, (E, H) C16 bodipy (BdpC16),
and (F, I) C5 bodipy (BdpC5). (J) Mean reduction in lipid reporter metabolism in ezetimibe vs wild type larvae. Error bars – standard deviation.
doi:10.1371/journal.pone.0012386.g006
Zebrafish Lipid Absorption
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intestine, the site of lipid absorption in zebrafish larvae (Figure 7A,
B). The effect of ezetimibe on AM1-43 uptake was dose res-
ponsive (Figure 7C, D).
To gain additional insight into the mechanism of action of
ezetimibe as well as the active compounds that affected
endocytosis (2, 7, A10), we compared their effect on AM1-43
metabolism with the effect of methyl-b-cyclodextrn (MbC), a
reagent that disrupts membrane lipid rafts by extracting
membrane cholesterol [36–38]. Pretreatment of zebrafish larvae
with MbC for four hours strongly inhibited endocytic uptake of
AM1-43 by enterocytes (Figure 7E). Recovery of endocytic
function was detected eight hours after MbC withdrawal
(Figure 7F), but was prevented in larvae unable to replenish
membrane cholesterol because of concomitant treatment with the
cholesterol synthesis inhibitor atorvastatin (Figure 7G). Atorvasta-
tin treatment on its own had no effect on AM1-43 processing
(Figure 7H). Like ezetimibe and the compounds that interfered
with AM1-43 processing, MbC inhibited C-16 bodipy metabo-
lism, and this too was reversed by repletion of membrane
cholesterol (Figure 7I). MbC had minimal effect on C-5 bodipy
metabolism (Figure 7IJ), most likely because enterocytes absorb
SCFA via passive diffusion.
Discussion
The principal findings of this study support the utility of
zebrafish screening assays for lead compounds that can be
developed into new drugs that inhibit lipid absorption. The screen
utilized fluorescent lipid analogs to directly assay intestinal lipid
absorption in larvae treated with novel chemical compounds, thus
distinguishing it from a study that examined the effects of known
drugs on endogenous yolk-lipid metabolism in younger zebrafish
larvae [39]. Using this screen we show that it is not only possible to
rapidly identify compounds that disrupt lipid metabolism with
comparable efficacy to ezetimibe, the most commonly used drug
in this class of pharmaceutical agents, but importantly, that
secondary assays allow their prioritization for subsequent evalu-
ation in mammalian models. Thus, even though a relatively high
percentage (1.3%) of the compounds analyzed in our primary
screen were initially scored as active, most of these were quickly
Figure 7. Membrane cholesterol depletion and ezetimibe inhibit endocytosis and fatty acid metabolism in zebrafish larvae. (A–H)
Histological cross sections through the anterior intestine of 6 day post-fertilization zebrafish larvae following ingestion and processing of the styryl
dye AM1-43. (A) Red fluorescent endocytic vesicles are evident in enterocytes of a wild type larva soaked in AM1-43 for 4 hours. (B–D) Ezetimibe
(50 uM) strongly inhibits AM1-43 uptake by enterocytes in a dose dependent manner. (E, F) A larva treated with methyl-b-cyclo-dextrin (MbC) shows
little AM1-43 uptake 4 hours after MbC withdrawal (MbC t4) whereas AM1-43 uptake can be detected at 8 hours after MbC withdra25al (MbC t8). (G)
Concomitant inhibition of cholesterol synthesis with atorvastatin (Atvn) prevents recovery of AM1-43 uptake following MbC withdrawal. (H) Atvn
alone has no effect on AM1-43 uptake. (I) Metabolism of the LCFA BdpC16 (I) but not SCFA BdpC5 (J), as measured by gallbladder and intestinal
fluorescence, is inhibited by membrane cholesterol depletion caused by MbC. (I) BdpC16 metabolism recovers following MbC withdrawal but not in
the presence of Atvn. (J) By contrast, recovery of BdpC5 metabolism from the effects of MbC that are independent of cholesterol depletion occurs
with or without Atvn treatment.
doi:10.1371/journal.pone.0012386.g007
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determined to be either false positives (1.1%), or were acutely toxic
to adult fish (0.1%). Of the remaining 8 compounds (0.2%), 1 was
shown to inhibit swallowing, thus leaving 7 compounds for more
detailed secondary analyses.
The secondary assays we devised took advantage of the ability
to conduct simple studies in zebrafish larvae that have well formed
organ systems with remarkably conserved physiology. The first set
of assays evaluated how each of the active compounds affected
metabolism of 3 different classes of lipids. 5 of the 7 compounds
studied functioned comparably to ezetimibe, which inhibited
processing of cholesterol, LCFA and phospholipids analogues. The
remaining 2 compounds inhibited processing of these lipids as well
as the SCFA C-5 bodipy whose absorption was unchanged even
following membrane disruption with MbC. Irrespective of the
cellular processes affected by these 2 compounds, the fact that they
inhibited uptake of a lipid (SCFA) that normally enters enterocytes
via simple diffusion warrants their elimination from consideration
for drug development.
The second secondary assay scored each compounds’ effect on
enterocyte endocytic pathways, as measure by AM1-43 processing.
Although not as easily quantified as fluorescent lipid metabolism,
the number of enterocyte fluorescent endocytic vesicles was
significantly reduced in larvae treated with 3 of the active
compounds. Although the effects of these 3 compounds were
comparable to ezetimibe, additional secondary assays eliminated
them from further consideration for drug testing. One of the three
compounds (compound 2) inhibited SCFA (Bodipy-C5) metabo-
lism. The remaining two compounds (compound 7, A10) inhibited
processing of a quenched fluorescent casein derivative that is
normally metabolized by pancreatic proteases secreted in response
to CCK [40], an intestinal hormone whose cognate receptor is
metabolized in pancreatic acinar cells and other tissues by
clathrin-dependent and clathrin-independent endocytic mecha-
nisms. Given their effects on enterocyte membrane dynamics (as
measured by AM1-43 processing), we speculate that compounds 7
and A10 interfered with CCK activity either by disrupting
endocytosis of the CCK receptor (since this been reported to
promote CCK signaling in pancreatic acinar cells; 40, 41), or by
altering ligand induced changes in CCK receptor oligomerization
or sequestration in the acinar cell plasma membrane [41,42].
Based on the secondary assays, the remaining 3 active
compounds (compounds 10, B10 and B11) could be considered
candidates for testing in mammals. Because all of the compounds
interfered with the absorption of phospholipid, cholesterol and
LCFA reporters, we initially thought that they non-specifically
interfered with enterocyte absorptive mechanisms, thus potentially
precluding their utility for drug development. Arguing against this,
we found that ezetimibe had comparable effects on lipid
absorption in zebrafish larvae. While this could indicate that
ezetimibe functions differently in zebrafish than in mammals,
recent studies suggest that ezetimibe interferes with dietary fat
absorption in mice and humans [43,44]. As these effects on fat
absorption were relatively modest, they may have been overlooked
in previous studies. Nonetheless, they are consistent with our
zebrafish data.
The comparable effects of ezetimibe and MbC on AM1-43
processing and fatty acid absorption lead us to speculate that
ezetimibe has a broader effect on enterocyte membrane dynamics
than previously recognized [27,45]. As result, ezetimibe might
interfere with the incorporation into lipid rafts of membrane
proteins that are required for fat absorption, in addition to its
effects on NPC1L1. A recent study suggests such a role for the SR-
BI/CLA-1 scavenger receptor [46], which has previously
implicated as playing a role in dietary fat absorption [47–49]. As
the screen compounds we considered best suited for testing in
mammals had a less pronounced effect on AM1-43 uptake than
ezetimibe, it is conceivable that they inhibit lipid absorption via
unique mechanisms.
Materials and Methods
Zebrafish husbandry and care of embryos and larvae has been
previously described [50]. All animals were handled in strict
accordance with good animal practice as defined by the relevant
national and/or local animal welfare bodies, and all animal work
was approved by the institutional IACUC.
5 day post-fertilization zebrafish larvae (n = 6) were added to
each well of a 96 well plate in 80 ul of E3 embryo media. To each
well, 20 ul of 125 uM stock of one test compound in 2% DMSO
was added (final concentration 25 uM). The larvae were incubated
overnight at 28 degrees celcius. The following morning PED-6
(Invitrogen) was added to each well at a final concentration of
0.1 ug/ml. Gallbladder and intestinal fluorescence was deter-
mined by visual inspection of each well 6 hours later using a
Olympus BX81 fluorescent inverted microscope. Compounds that
caused a qualitative reduction in gallbladder and intestinal
fluorescence were considered positive in the original primary
screen. As not all larvae in the 96 well plates could be confidently
scored, a compound was considered active if gallbladder
fluorescence was reduced in at least 3 well visualized larvae.
Active compounds identified in the primary screen were retested
in a visual dose response assay. Most compounds were tested at
6.25 uM to 100 uM. Others were tested at 25 uM –100 uM. The
dose response assay was conducted identically to the primary
screen. Compounds were considered active if all larvae showed
inhibition of gallbladder and intestinal fluorescence. For quanti-
fication of gallbladder and intestinal fluorescence individual larvae
were removed from the 96 well plates and arrayed on a depression
slide and imaged using an Olympus BX71 fluorescent microscope.
Total gallbladder and intestinal fluorescence in digital images of
each larva was quantified using Slidebook software.
Commercially acquired zetimibe tablets were crushed with a
glass rod in a 10 mL round bottom flask, taken up into DMSO
(4 mL), and stirred for 1 h at 23uC. The solution was filtered with
an HPLC filter and water added (1 mL). The sample was purified
utilizing preparative LC-MS and 8 mg of zetimibe was obtained.
Zetimibe obtained employing these conditions was found to be
analytically pure by LC-MS analysis. For all assays, 5 day post-
fertilization zebrafish larvae were incubated overnight in purified
ezitimibe at the test concentrations indicated and then subjected to
assays as described for the compound treated larvae.
Assays of short chain fatty acid (SCFA; Bodipy-C5), long chain
fatty acid (LCFA; Bodipy-C16) and cholesterol (NBD-cholesterol)
were conducted identically to the primary screen as previously
reported [19]. All reagents were purchased from Invitrogen. For
the digestive protease assay, larvae were treated identically to the
primary screen but instead of PED-6 the larvae were soaked in
quenched bodipy-casein (EnzCheck- Invitrogen) as recently
described [31]. For the swallowing assay, compound treated
larvae were soaked in fluorescent microscpheres (In vitrogen) for
5 hours. The larvae were then washed and intestinal fluorescence
quantified microscopically as previously noted. The AM1-43 assay
was performed as previously described using larvae treated
overnight with either the active compounds or ezetimibe [30].
Qualitative analysis of endocytosis was performed by examining
enterocyte AM1-43 uptake in a minimum of 10 histological cross
sections from 7 larvae within each experimental group. When
indicated, larvae were incubated in methyl-b-cyclodextrin (Ad-
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vasep-7; Biotium, Inc.) for 4 hours, washed for 2 hours and then
soaked in AM1-43 with or without Atorvastatin (50 uM) as
previously described [30]. Histological analyses were performed as
previously reported [30].
Compounds 10, B10, and B11 were analyzed by LC/MS for
purity and integrity using a Sunfire C18 5 mm column
(4.6650 mm) and a gradient elution system of CH3CN: H20
(10% to 90% over 10 minutes). Compound 10 was 100% pure by
diode array detection, with molecular ion detected at 473.2 (M+1).
Compound 13 was 100% pure by diode array detection, with
molecular ion detected at 418.3 (M+1). Compound 14 was 88%
pure by diode array detection, with molecular ion detected at
349.2 (M+1). The activity of each compound was confirmed in
repeat assays using either the Bodipy-C16 or PED-6 lipid.
Supporting Information
Table S1 Active compounds derived from primary and
secondary screening assays.
Found at: doi:10.1371/journal.pone.0012386.s001 (0.06 MB
DOC)
Figure S1 Lipid reporter metabolism in ezetimibe and com-
pound treated larvae: Values represent intestinal and gallbladder
fluorescence. 4 larvae analyzed at each time point. Error bars are
standard deviation from the mean of 3 independent experiments.
Found at: doi:10.1371/journal.pone.0012386.s002 (2.27 MB
DOC)
Figure S2 Swallowing assay in live zebrafish larvae: (A–F) Bright
field and corresponding fluorescent images of control and
representative compound treated 6 dpf zebrafish larvae following
ingestion of fluorescent microscphreres. (G, H) Quantification of
intestinal fluorescence in compound treated and sibling control
larvae. Compound 1 strongly inhibits swallowing whereas
swallowing is normal in larvae treated with compound 2. Each
data point represents mean intestinal fluorescence of 6 larvae.
Found at: doi:10.1371/journal.pone.0012386.s003 (0.32 MB
DOC)
Figure S3 Conserved ezetimibe binding domain in human and
zebrafish NPC1L1 protein: The 62 amino acid tract of NPC1L1
shown to mediate binding of ezetimibe (amino acids 510 to 572).
41 of the amino acids in the human and zebrafish proteins are
identical, 11 are conserved and 10 and non-conserved. Conserved
phenylalanine (F) and methionine (M) residues required for high-
affinity binding are shown in red.
Found at: doi:10.1371/journal.pone.0012386.s004 (0.02 MB
DOC)
Figure S4 Ezetimibe inhibits cholesterol metabolism in zebafish
larvae: Mean percent inhibition of intestinal and gallbladder
fluorescence in ezetimibe treated larvae (6.25 uM, 12.5 uM,
25 uM and 37.5 uM). N = 6 larvae for each dose. Error bars
indicate standard deviation.
Found at: doi:10.1371/journal.pone.0012386.s005 (0.06 MB
DOC)
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